Everest Medicines Limited
Everest Medicines Limited Fundamental Analysis
Everest Medicines Limited (1952.HK) shows moderate financial fundamentals with a PE ratio of -25.48, profit margin of -70.03%, and ROE of -11.43%. The company generates $0.7B in annual revenue with moderate year-over-year growth of 4.61%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -32.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1952.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1952.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent1952.HK trades at attractive valuation levels.
Growth Score
Weak1952.HK faces weak or negative growth trends.
Financial Health Score
Excellent1952.HK maintains a strong and stable balance sheet.
Profitability Score
Weak1952.HK struggles to sustain strong margins.
Key Financial Metrics
Is 1952.HK Expensive or Cheap?
P/E Ratio
1952.HK trades at -25.48 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 1952.HK's PEG of -1.27 indicates potential undervaluation.
Price to Book
The market values Everest Medicines Limited at 2.95 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -55.67 times EBITDA. This is generally considered low.
How Well Does 1952.HK Make Money?
Net Profit Margin
For every $100 in sales, Everest Medicines Limited keeps $-70.03 as profit after all expenses.
Operating Margin
Core operations generate -83.86 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-11.43 in profit for every $100 of shareholder equity.
ROA
Everest Medicines Limited generates $-9.21 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Everest Medicines Limited generates limited operating cash flow of $-197.04M, signaling weaker underlying cash strength.
Free Cash Flow
Everest Medicines Limited generates weak or negative free cash flow of $-223.49M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.63 in free cash annually.
FCF Yield
1952.HK converts -1.64% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-25.48
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.27
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.95
vs 25 benchmark
P/S Ratio
Price to sales ratio
19.38
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.18
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.46
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.11
vs 25 benchmark
ROA
Return on assets percentage
-0.09
vs 25 benchmark
ROCE
Return on capital employed
-0.12
vs 25 benchmark
How 1952.HK Stacks Against Its Sector Peers
| Metric | 1952.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -25.48 | 28.31 | Better (Cheaper) |
| ROE | -11.43% | 699.00% | Weak |
| Net Margin | -70.03% | -130884.00% (disorted) | Weak |
| Debt/Equity | 0.18 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 5.46 | 2775.16 | Strong Liquidity |
| ROA | -9.21% | -14469.00% (disorted) | Weak |
1952.HK outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Everest Medicines Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
0.00%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-375.82%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-577.54%
Industry Style: Defensive, Growth, Innovation
Declining